Bleeding Risk in Patients with Peripheral Arterial Disease

Area of Science:

• Cardiovascular Medicine
• Vascular Surgery
• Pharmacology

Background:

• Patients with peripheral arterial disease (PAD) face high risks of major adverse cardiac events (MACE) and major adverse limb events (MALE).
• Antithrombotic therapies reduce MACE and MALE in PAD patients, especially after revascularization, but increase bleeding risk.
• Current antithrombotic strategies and revascularization procedures heighten hemorrhagic risk, necessitating careful risk assessment.

Purpose of the Study:

• To highlight the critical need for targeted risk assessment scores in PAD patients.
• To emphasize the importance of balancing antithrombotic therapy benefits with bleeding risks.
• To advocate for the development of precise and adaptable risk scores for clinical decision-making.

Main Methods:

• Review of current antithrombotic therapies and their associated risks in PAD.
• Analysis of the limitations and variability of existing clinical risk scores.
• Discussion on the characteristics of an ideal risk score for PAD patients.

Main Results:

• Aggressive antithrombotic therapies increase bleeding complications in PAD patients.
• Existing clinical risk scores have limitations and inter-score variability.
• There is a need for scores that identify modifiable bleeding risk factors and high-risk patients.

Conclusions:

• Developing specific, functional, validated, and precise risk scores is essential for PAD management.
• Risk scores should be adaptable to diverse clinical contexts and populations.
• Accurate risk stratification is key to optimizing antithrombotic therapy and patient outcomes in PAD.